Classes
DEA Class; Rx
Common Brand Names; Voquezna Dual Pak
- Potassium-Competitive Acid Blockers;
- H pylori Agents
Description
Vonoprazan
Potassium-competitive acid blocker (PCAB)
Suppresses basal and stimulated gastric acid secretion at secretory surface of gastric parietal cell through inhibition of the H+,K+-ATPase enzyme system in a potassium-competitive manner
Because this enzyme is regarded as the acid (proton) pump within the parietal cell, vonoprazan has been characterized as a type of gastric proton-pump inhibitor, as it blocks the final step of acid production
Does not require activation by acid; may selectively concentrate in parietal cells in both resting and stimulated states
Binds to active proton pumps in noncovalent and reversible manner
Amoxicillin
Ampicillin derivative; elicits antibacterial effect by binding to penicillin-binding proteins and inhibiting biosynthesis of cell wall
Indications
Indicated for treatment of Helicobacter pylori (H pylori) infection
Contraindications
Known hypersensitivity to any component – vonoprazan, or amoxicillin (or other beta-lactam antibacterials [eg, penicillins, cephalosporins])
Rilpivirine-containing products, owing to inhibition of gastric pH by vonoprazan
Adverse Effects
- Diarrhea (5.2%)
- Abdominal pain (2.6%)
- Vulvovaginal candidiasis (2%)
- Nasopharyngitis (2%)
- Headache (1.4%)
- Hypertension (1.1%)
- Blood and lymphatic system disorders: Anemia, leukocytosis, leukopenia, neutropenia
- Cardiac disorders: QT prolongation, tachycardia
- Eye disorders: Orbital edema
- Gastrointestinal disorders: Abdominal distention, constipation, dry mouth, duodenal polyp, duodenal ulcer, dyspepsia, flatulence, gastric ulcer, gastroesophageal reflux disease, hematochezia, large intestine polyp, nausea, rectal polyp, stomatitis, tongue discomfort, vomiting
- General disorders and administration site conditions: Fatigue, pyrexia
- Immune system disorders: Drug hypersensitivity
- Infections and infestations: Anal fungal infection, gastrointestinal viral infection, oral fungal infection, pneumonia, tongue fungal infection, upper respiratory tract infection, urinary tract infection, viral infection
- Investigations: Liver function test abnormal
- Metabolism and nutrition disorders: Decreased appetite
- Musculoskeletal system: Bone fracture
- Nervous system disorders: Ageusia, dizziness, tension headache
- Psychiatric disorders: Anxiety, depression, insomnia
- Renal and urinary disorders: Renal hypertrophy, tubulointerstitial nephritis
- Reproductive system and breast disorders: Vaginal discharge
- Respiratory, thoracic, and mediastinal disorders: Cough, nasal polyps, oropharyngeal pain
- Skin and subcutaneous tissue disorders: Dermatitis, dry skin, rash
- Dysgeusia (0.6%)
Warnings
Serious and occasionally fatal hypersensitivity reactions (eg, anaphylaxis, anaphylactic shock, rash, erythema multiforme, and Henoch-Schonlein purpura) reported with components; discontinue immediately and institute appropriate treatment if hypersensitivity occurs
Severe cutaneous adverse reactions (SCAR), including SJS and TEN, reported with all components; additionally, DRESS and AGEP have been reported with amoxicillin; discontinue at first signs of SCAR
Clostridioides difficile–associated diarrhea (CDAD) reported with acid-suppressing therapies and nearly all antibacterial agents; CDAD must be considered in all patients who present with diarrhea following antibacterial use; careful medical history necessary since CDAD reported to occur over 2 months after administration of antibacterial agents; if CDAD confirmed, discontinue, and implement appropriate management
High percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash; avoid in patients with mononucleosis
Prescribing this regimen in absence of proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit and increases risk for drug-resistant bacteria
Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity; increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors; assess CgA levels at least 14 days after treatment, and consider repeating test if initial CgA levels are high
Glucose tests: High urine concentrations of amoxicillin may cause false-positive results when using glucose tests based on the Benedict copper reduction reaction that determines the amount of reducing substances, like glucose, in the urine; use enzymatic glucose oxidase reactions instead while taking amoxicillin
Pregnancy and Lactation
Available data from pharmacovigilance reports with vonoprazan use in pregnant females are not sufficient to evaluate for drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes
There are no data regarding the presence of vonoprazan in human milk, the effects on the breastfed infant or the effects on milk production
Data from published clinical lactation study indicate that amoxicillin is present in human milk
Maximum Dosage
Dose: vonoprazan 20 mg PO BID plus amoxicillin 1000 mg PO TID x 14 days
Pediatric
Safety and efficacy not established
How supplied
Vonoprazan/amoxicillin
copackaged tablets and capsules
- tablets: vonoprazan 20 mg
- capsules: amoxicillin 500 mg
- Carton contains 14 daily administration packs for twice daily dosing of vonoprazan and 3 times daily dosing of amoxicillin